Cargando…

Letter to the Editor From Chatelain et al: “Weekly Somapacitan Is Effective and Well Tolerated in Children With GH Deficiency: The Randomized Phase 3 REAL4 Trial”

Detalles Bibliográficos
Autores principales:	Chatelain, Pierre, Kjelgaard-Hansen, Mads, Sprogøe, Kennett
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2023
Materias:	Letter to the Editor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10348463/ https://www.ncbi.nlm.nih.gov/pubmed/36869710 http://dx.doi.org/10.1210/clinem/dgad096

Ejemplares similares

Response to Letter to the Editor From Chatelain et al: “Weekly Somapacitan Is Effective and Well Tolerated in Children With GH Deficiency: The Randomized Phase 3 REAL4 Trial”
por: Miller, Bradley S, et al.
Publicado: (2023)

Once-weekly Somapacitan is Effective and Well Tolerated in Adults with GH Deficiency: A Randomized Phase 3 Trial
por: Johannsson, Gudmundur, et al.
Publicado: (2020)

Weekly Somapacitan is Effective and Well Tolerated in Children With GH Deficiency: The Randomized Phase 3 REAL4 Trial
por: Miller, Bradley S, et al.
Publicado: (2022)

MON-265 Once-Weekly Somapacitan in Japanese Adults with GH Deficiency Was Well Tolerated, with Similar Efficacy to Daily GH: A Randomized Trial
por: Otsuka, Fumio, et al.
Publicado: (2020)

RF14 | LBMON195 Once-weekly Somapacitan Is Effective And Well Tolerated In Children With GH Deficiency: A Randomized Phase 3 Trial
por: Miller, Bradley, et al.
Publicado: (2022)

Dose–exposure–IGF-I response of once-weekly somapacitan in adults with GH deficiency
por: Kildemoes, Rasmus Juul, et al.
Publicado: (2022)

Safety and convenience of once-weekly somapacitan in adult GH deficiency: a 26-week randomized, controlled trial
por: Johannsson, Gudmundur, et al.
Publicado: (2018)

Once-Weekly Somapacitan vs Daily GH in Children With GH Deficiency: Results From a Randomized Phase 2 Trial
por: Sävendahl, Lars, et al.
Publicado: (2020)

Corrigendum to: “Once-Weekly Somapacitan vs Daily GH in Children With GH Deficiency: Results From a Randomized Phase 2 Trial”
Publicado: (2020)

Effective GH Replacement With Once-weekly Somapacitan vs Daily GH in Children with GHD: 3-year Results From REAL 3
por: Sävendahl, Lars, et al.
Publicado: (2021)

SAT642 Effective Gh Replacement With Once-weekly Somapacitan In Children With Gh Deficiency: 2-year Results From Real4
por: Miller, Bradley Scott, et al.
Publicado: (2023)

Model-Based Analysis of IGF-I Response, Dosing, and Monitoring for Once-Weekly Somapacitan in Children With GH Deficiency
por: Kildemoes, Rasmus J, et al.
Publicado: (2023)

Weekly Somapacitan in GH Deficiency: 4-Year Efficacy, Safety, and Treatment/Disease Burden Results From REAL 3
por: Sävendahl, Lars, et al.
Publicado: (2023)

THU174 Model-Based Analysis Of IGF-I Response, Dosing, And Monitoring For Once-Weekly Somapacitan In Children With GH Deficiency
por: Kildemoes, Rasmus Juul, et al.
Publicado: (2023)

Effective GH Replacement With Somapacitan in Children With GHD: REAL4 2-year Results and After Switch From Daily GH
por: Miller, Bradley S, et al.
Publicado: (2023)

Correction to: “Effective GH Replacement With Somapacitan in Children With GHD: REAL4 2-year Results and After Switch From Daily GH”
Publicado: (2023)

Optimal Monitoring of Weekly IGF-I Levels During Growth Hormone Therapy With Once-Weekly Somapacitan
por: Juul Kildemoes, Rasmus, et al.
Publicado: (2020)

Weekly somapacitan had no adverse effects on glucose metabolism in adults with growth hormone deficiency
por: Takahashi, Yutaka, et al.
Publicado: (2022)

Response letter regarding the letter to the editors by Brown et al.
por: Taylor, Sylvia, et al.
Publicado: (2016)

Letter to the editor: in response to Alstrup et. al.
por: Slagt, Cor, et al.
Publicado: (2019)

Letter to the Editor response: Nygaard et al.
por: Towfic, F., et al.
Publicado: (2017)

Response to the Letter to the Editor by Eberhard et al.
por: Bottomley, Christian, et al.
Publicado: (2017)

Letter to the Editor in Response to Khazanchi et al.
por: Nayak, Aditi, et al.
Publicado: (2021)

Letter to the editor from Pant et al
por: Pant, Shubham, et al.
Publicado: (2021)

Letter to the Editor: In Response to Sarkar et al.
por: Pokhrel, Damodar, et al.
Publicado: (2021)

Reply to Letter to the Editor by Yin et al.
por: Coleman, Brenda L., et al.
Publicado: (2021)

Reply to the letter to the editor by Mungmunpuntipantip et al.
por: Longo, M., et al.
Publicado: (2021)

Letter to the Editor in Response to Zhou et al
por: Troth, Sean, et al.
Publicado: (2021)

Letter to the Editor from Colle et al
por: Colle, Raphael, et al.
Publicado: (2021)

Response to the Letter to the Editor by Mungmunpuntipantip et al
por: Stamenković, Marija, et al.
Publicado: (2022)

Letter to the Editor Reply: Kleebayoon et al.
por: Meador, Catherine B., et al.
Publicado: (2023)

SAT-091 First Report of Disease-Specific Patient-Reported Outcomes from a Randomized Phase 2 Trial of Once-Weekly Somapacitan vs Daily GH in Children with GHD
por: Brod, Meryl, et al.
Publicado: (2020)

A Letter to the Editor on the Article by Farnam et al
por: Rutte, Anne, et al.
Publicado: (2015)

Letter to the Editor re: Biglari et al. (2016)
por: Zura, Robert, et al.
Publicado: (2016)

Letter to the editor according to the study of Schwarze et al.
por: Sinnema, Marscha
Publicado: (2019)

Letter to the editor in response to Buja et al. 2020
por: Parmar, Dilen, et al.
Publicado: (2021)

A response to the letter to the editor by Driscoll et al.
por: Saber, Anne T., et al.
Publicado: (2020)

Response to Letter to Editor by Dr. Aminnejad et al.
por: Shahrokhirad, Reyhaneh, et al.
Publicado: (2019)

Letter to the Editor in response to Chen et al. 2020
por: Ponnampalam, Jaya, et al.
Publicado: (2020)

Letter to the editor in response to Komen et al. 2021
por: Kumar, Niraj S, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_opgbovo1n5js7lk589covoh1fa